40% revenue growth, margin headwind from ramp-ups and insurance delays
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 7/10
Grade B
No quantified FY27 guidance. Q1 margin (20.1%) vs Q2 claim of stability (20.5%) masks compression in AP. Capex plan stated (₹1,100 Cr / 18 mo) but execution timeline vague.
Cautiously Optimistic
next 1–2 quarters
Optimistic
multi-year
Strong 40% revenue growth driven by unit ramp-ups and volume expansion, but PAT growth muted at 3.6% due to margin compression (doubtful debt ₹7.5 Cr, fixed costs in new units, insurance delays blocking patient flow in Thane/Mahadevapura). Management expects stabilization in 3–4 quarters, but execution risk is real: six acquisitions/O&M deals in parallel, Sarvottam at 53–67x EBITDA, and regulatory uncertainty in Kerala.
₹1344.4 Cr
Revenue · +39.9% YoY₹74.6 Cr
Reported PAT · +3.6% YoYCompressing
Margins · vs guidance: MixedDid the claims hold up?
Consolidated revenue ₹1,344 Cr, +39.9% YoY, +14% QoQ
METDelivered consolidated revenue ₹1,344.4 Cr matches guidance
EBITDA margin 20.5% in Q2 vs 20.1% in Q1, stable
OVERSTATEDMargin compression in AP and ramp-up units; doubtful debt INR7.5 Cr dragging consolidated margins
Kondapur revenue grew 70% in 3 months since opening
METKondapur ramp documented; but margins fell due to high fixed costs and new programs (Vizag, Anantapur)
Q2 is bottom quarter for losses in new units; margins return to 30% in 3–4 quarters
OVERSTATEDManagement assertion, not yet proven; similar claims made for Thane (insurance blocks), Mahadevapura (14-month payback for doctors)
PAT ₹76 Cr standalone YoY growth +8.5% (reported EPS ₹1.8, +8.5% YoY)
OVERSTATEDStandalone PAT growth only 5.5% (from ₹72 Cr in Q2 FY26 to ₹76 Cr); consolidated PAT ₹74.6 Cr, +3.6% YoY — muted
Earnings quality
What changed since the last call
Doubtful debt provision materialized in Q2
DowngradeNot mentioned in Q1 call; INR7.5 Cr in Q2 due to AP government payment delays. Q3 recovery assumed but unproven.
Kondapur margins below expectation despite 70% ramp
DowngradeRevenue grew 70%, but EBITDA margin fell in Andhra cluster to ~22% vs 24–25% prior. Fixed costs and new programs (Vizag, Anantapur) cited; recovery to 30% pushed to 3–4 quarters (vs prior 'next quarter' tone).
Insurance empanelment delays extended
DowngradeThane still not done; Mahadevapura down to 2–3 insurers. Management said 'ongoing', no clear end date. Prior call suggested near-term resolution.
Sarvottam acquisition at higher-than-typical entry multiple
New₹80 Cr for 51% stake (₹157 Cr implied valuation for ₹1.2–1.5 Cr EBITDA = 105–131x). Not disclosed in Q1; new portfolio risk.
Capex plan clarified at ₹1,100 Cr over 18 months
Maintained3 projects (Secunderabad, Rajahmund, Kondapur). Management reiterated no new hospital commissioning until stabilization (FY28+), aligning with prior guidance.
The Q&A
Analysts pressed hard on margin trajectory (Karan Vora, Damayanti Kerai), insurance delays (Rahul Jeewani), Kondapur occupancy (Yuvraj Sehrawat), and acquisition multiples (Simran Thakkar). Management mostly held ground but conceded margins are bottom in Q2, doubtful debt is a headwind, and insurance is 'ongoing'. On Sarvottam multiple, MD defended confidence in ramp but lacked concrete proof.
Anti-cancer drug margin impact — Shubh Kalra, Asit C. Mehra
DodgedFinal details yet to be disclosed (November 9th). Oncology not a big part of revenue; impact may not be significant. Management evaluating mitigation (package rate revisions).
Kondapur ramp & margins — Karan Vora, Goldman Sachs
AnsweredQ1 Kondapur ₹623 Cr → Q2 ₹700 Cr. Revenue grew 70% in 3 months. But EBITDA margin dipped due to fixed costs, new programs (Vizag, Anantapur). Expected to normalize over 3–4 quarters to 30%.
AP cluster margins — Karan Vora, Goldman Sachs
AnsweredTwo new programs started (Vizag, Anantapur); fixed costs higher. Over 2–3 quarters should normalize. PBDT (doubtful debt from gov business) ₹8 Cr hit in Q2, reversal expected Q3 onwards.
Kondapur occupancy & beds — Rahul Jeewani, IIFL
Answered500 beds commissioned, 70% occupancy. Remaining beds (old hospital) under review; will commission next year or next few quarters. Total potential ₹1,200 Cr revenue (5-year target).
Insurance empanelment status — Rahul Jeewani, IIFL
PartialThane still in struggle. Mahadevapura down to 2–3 insurance companies. Negotiations ongoing; no fixed timeline. Expected to progress towards end of year.
Electronic City breakeven — Rahul Jeewani, IIFL
AnsweredBroke even in September 2026. EBITDA positive expected Q3. Q4 safer assumption given buffer for unforeseen.
Transplant market size & economics — Damayanti Kerai, HSBC
PartialKidney transplants in most units, liver/heart/lung in 5–8 units. Don't track EBITDA by therapy, but high realization and high cost. Net positive contribution.
Margin recovery timeline — Damayanti Kerai, HSBC
AnsweredExcept Electronic City, all EBITDA positive. Electronic City Q4 likely. Q2 is bottom; trajectory upward unless new hospital commissioned.
Secunderabad capacity & ramp — Karan Vora, Goldman Sachs
Answered250 beds non-consensus (dialysis machines). Renovations on old hospital 250 beds. Onco expansion underway. Sports medicine program launched. Next phase adds 250 more.
Bangalore cluster operationalization — Yuvraj Sehrawat, ChrysCaptial
AnsweredThane, Bengaluru, Electronic City first new units; 70% occupancy target in 4–6 years. Some therapies need standalone presence (not multi-campus). Gradual ramp expected.
Rental cost escalation at Kondapur — Anshul Agrawal, Emkay
AnsweredKondapur rents only from June (3 months impact vs 1 month Q1). ₹5.5 Cr per month rental. Established; no further escalation. Merger of rental partner being evaluated.
Call option accounting transparency — Anshul Agrawal, Emkay
AnsweredCall option fair value ₹13.2 Cr in Q2, accounted as extraordinary item below EBITDA. Corporate costs not assigned to call option revenue.
Capex breakup and future guidance — Simran Thakkar, Beas Capital
AnsweredH1: INR275 Cr other assets, INR300 Cr Kondapur. Next 18 mo: ₹1,100 Cr on Secunderabad, Rajahmund, Kondapur. No new hospital till stabilization.
Long-term debt and utilization — Simran Thakkar, Beas Capital
AnsweredQIP money marked for general purposes (loss funding, minority acquisitions). Long-term debt for capex. 25% of QIP allocated to general purposes.
Sarvottam acquisition valuation — Simran Thakkar, Beas Capital
PartialMonthly revenue INR8–10 Cr, EBITDA INR1.2–1.5 Cr. Confident can ramp to INR7–8 Cr/month. Remaining 49% with existing doctor, option to buy at fixed multiples, no immediate plan.
Net debt and leverage — Rahul Jeewani, IIFL
AnsweredNet debt ₹2,150 Cr. Net debt/EBITDA ~1.9x. Merger of rental partner may bring ₹400 Cr debt, loss only GST (18% saving).
Future expansion markets — Rahul Jeewani, IIFL
AnsweredSecunderabad, Kondapur core markets. Rajahmund, Ongole in next 4–5 months. 400–500 beds addition over 24 months. Then stabilize and prepare for FY28+ expansion (Chennai, Kerala, etc.).
Kerala regulatory risk — Rahul Jeewani, IIFL
DodgedUncertain. Many governments considering transparency. KIMS yet to figure out method or impact. No visibility on regulation or outcome.
Guidance
Kondapur ₹1,200 Cr revenue potential (5-year target)
MediumCurrent ramp-up on track; 70% growth in 3 months. Assumes 500-bed + expansion to 1,250 beds. Long-term directional, not near-term quantified.
Stable growth across units; new-unit ramp expected to stabilize by end FY27
MediumManagement expects margin recovery post-stabilization (Q3–Q4 FY27 onwards). Capex-heavy phase for next 18 months; growth moderated post capex cycle.
Telangana 30% EBITDA margin at scale (Kondapur, Secunderabad)
MediumAspirational. Kondapur currently dipped to ~20%; management expects 3–4 quarters to return to 30%. Unproven timeline.
AP 25% margin by FY27 end; Kerala 20–22% at maturity
LowAP currently ~22%, dragged by new programs, insurance delays. Kerala data limited (only 1 O&M hospital). Regulatory uncertainty (pricing control) adds risk.
₹1,100 Cr capex over next 18 months (Secunderabad, Rajahmund, Kondapur)
HighH1 capex ₹650 Cr (₹300 Kondapur, ₹275 other). Debt-funded; long-term borrowing ₹3,600 Cr raised. Capital-heavy growth phase through FY27.
No new hospital commissioning until stabilization (FY28+); greenfield/M&A resume post-FY27
HighManagement reiterated 'stabilization first' strategy. Chennai 300-bed target FY29 onwards. Shift from capex-led to M&A-led post-FY27.
Risks the call surfaced
Insurance empanelment
HighThane & Mahadevapura unable to tie up major insurers (Thane none, Maha 2–3 only). Government business high but slow payers (PBDT ₹7.5 Cr Q2). Revenue and margins pressured until resolved.
Margin recovery timeline
HighNew-unit ramps (Kondapur, Secunderabad, Bengaluru, Thane, Mahadevapura) all sub-scale with high fixed costs. Management claims Q2 is bottom and margins return to 30% in 3–4 quarters, but AP currently ~22%, Kondapur dipped despite 70% growth. If insurance delays persist or new programs drag longer, margin recovery pushed beyond FY27 end.
Acquisition valuation
HighSarvottam Healthcare: ₹80 Cr for 51% stake (₹157 Cr implied EV for ₹1.2–1.5 Cr EBITDA = 105–131x EBITDA). Management confident in ramp to ₹7–8 Cr/month, but execution unproven. 6 concurrent acquisitions (Sarvottam, Arete, Westfort, Abhinav Sangli, Kompally, Sikhara) + 28 existing hospitals create integration bandwidth risk.
Capex intensity and leverage
Medium₹1,100 Cr capex over 18 months; ₹3,600 Cr long-term debt raised. Net debt ₹2,150 Cr (~1.9x EBITDA). If new hospitals ramp slower (insurance delays, market saturation, physician availability), leverage will remain elevated, limiting financial flexibility.
Regulatory and pricing pressure
MediumAnti-cancer drug trade margin regulation (announcement Nov 9th). Kerala government considering private hospital pricing control. Management stated no visibility on impact but acknowledged risk. Could reset oncology and other high-margin segments.
Management
Score 7/10. Clear on financials (revenue, EBITDA, capex); transparent on challenges (insurance delays, PBDT, margin compression in ramps). Deferred anti-cancer drug impact (Nov 9th), unclear on Kerala regulation. Confident tone may overstate execution readiness given 6 concurrent acquisitions. Track record mixed. Sai Veera Hospital (Anantapur) doubled capacity on time. Kondapur ramp-up documented (70% growth in 3 months). But Electronic City took longer to breakeven; Thane and Mahadevapura still struggling on insurance after 12–15 months. Doubtful debt provision not previously highlighted.
1 · Nov 09, 2026
Anti-cancer drug trade margin cap impact to be disclosed
2 · Q3 FY27
Electronic City EBITDA breakeven; Thane insurance empanelment complete
3 · Q3/Q4 FY27
Doubtful debt reversal expected; Insurance settlement completion
Management expects stabilization in 3–4 quarters, but execution risk is real: six acquisitions/O&M deals in parallel, Sarvottam at 53–67x EBITDA, and regulatory uncertainty in Kerala.
Informational and educational content only. Not investment advice.